Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.
Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.
Transcript
What is known about the adverse events of CAR T treatments and how they are handled?
There are some adverse events of special interest, because they’re not seen with chemotherapy or with the currently available therapies that we use. They are cytokine release syndrome and neurotoxic syndrome.
So, the cytokine release syndrome is akin to what you would expect in a patient if they had an overwhelming infection or severe sepsis: low/high fever, low blood pressure, sometimes capillary leak syndrome—meaning egress of fluid into lungs and tissues, which leads to respiratory failure and kidney failure and organ failure and death, if untreated. So, one has to know how to monitor the patients for this syndrome. By and large, severe cytokine release syndrome that is life threatening is fortunately less frequent than all grades. And, it varies from T-cell product to T-cell product, but we’ve learned that it can be treated with the IL-6 blocking antibody, tocilizumab, successfully in almost all cases. So, most of the recent trials have not shown any deaths from cytokine release syndrome, now that we recognize the syndrome as a consequence of T-cell therapy and we’ve learned how to manage it.
The neurotoxic events we don’t know really how to predict. We don’t know how to manage them, because we don’t understand them. Although, the good thing is, they’re generally reversible within a week without any treatment; although, frequently patients are given some steroids to try to blunt T-cell activity, presuming that’s what’s mediating the syndrome. And it can vary from just a mild confusion, word-finding difficulty, to coma. So, there’s a spectrum of severity. Fortunately, most of the events are not severe. Very rare that someone has a mortality to central nervous system side effects.
They’re unique toxicities that physicians and providers will have to be educated about when they begin to use this kind of therapy or manage patients that have had this kind of therapy.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More